Having done a lot of work on measuring performance, I don’t think this is very common. There are very few tasks that AI can do where there is not an upward trajectory. You can find tasks that no AI can do, or where there is saturation, but otherwise you get improvement over time.
HEALTHCARE AI
-
AI Benefits Breast Cancer Screening: New Reports and Editorial
By
–
This is far from an exhaustive list – look at my past tweets to find dozens more academics doing interesting work on the topic
-
AI Identifies Blood Stem Cell Clones Mechanism in Aortic Aneurysms
By
–
We don't measure blood stem cell clones (CHIP) in the clinic. But some are linked with fast, expanding abdominal aortic aneurysms, identification of an underlying mechanism, and a potential preventive treatment @jclinicalinvest https://
jci.org/articles/view/
206748
… -
AI Role in Major For-Profit Hospital Chain Healthcare
By
–
How AI is already playing a role at the country's largest for-profit hospital chain
#AI #AIio #AIInnovation #ML #DataScience #Futureofwork @demishassabis @Ronald_vanLoon @TamaraMcCleary @geoffreyhinton @goodfellow_ian @jeffdean @erikbryn -
PBS NewsHour segment explores Super Agers aging research
By
–
At @PBS last night, a segment on Super Agers @NewsHour with @WmBrangham
-
AI Optimizes Clinical Trial Design to Find Patients Faster
By
–
AI optimizes clinical trial design to find the right patients faster and reduce failure rates.
-
Autonomous AI Managing Patient Care: FDA Regulatory Challenges
By
–
What about "Autonomous AI Managing Patient Care," as seen with the ongoing Utah @Doctronic program for prescription renewals? https://
nejm.org/doi/full/10.10
56/NEJMp2601148?query=WB
… @NEJM "The FDA may decide to look the other way and allow this experiment to continue, leaving clinicians and patients without -
AI Accelerates Drug Development Timelines From Lab to Patients
By
–
Life sciences AI is shortening the time from lab to patients. Partner content with @Siemens.
— Lucian Fogoros (@fogoros) 18 avril 2026
Traditional drug development: 10-15 years, billions in costs.
AI-accelerated development: compressed timelines, optimized trials.
The difference is measured in lives saved. #sie_HM. pic.twitter.com/8ehFGDJjwsLife sciences AI is shortening the time from lab to patients. Partner content with @Siemens
.
Traditional drug development: 10-15 years, billions in costs.
AI-accelerated development: compressed timelines, optimized trials.
The difference is measured in lives saved. #sie_HM. -
Rosalind Project: Ambitious Drug Discovery Effort and Research Implications
By
–
Thanks Maggie for reaching out. Rosalind seems like a very ambitious and worthwhile effort, and I am very hopeful about what may come out of it. However, drug discovery is a far cry from deep fundamental science research. Also, based on my first hand experience with some of the
-
Rosalind Project: Drug Discovery and Fundamental AI Research Challenges
By
–
Thanks Maggie for reaching out. Rosalind seems like a very ambitious and worthwhile effort, and I am very hopeful about what may come out of it. However, drug discovery is a far cry from deep fundamental science research. Also, based on my first hand experience with some of the